Teamsters Local 404 Health Services and Insurance Plan v. King Pharmaceuticals, Inc.

E-Law Admin/ Oktober 16, 2018/ Arzneimittelrecht Schweiz/ 0Kommentare

Teamsters Local 404 Health Services and Insurance Plan v. King Pharmaceuticals, Inc., 16?791 Read Teamsters Local 404 Health Services and Insurance Plan v. King Pharmaceuticals, Inc., 16?791 Held that it was proper to remand to New York state court a case in which a labor union health plan sought disclosure of a patent dispute settlement agreement between pharmaceutical companies and

Weiterlesen

AmGen Inc. v. Sandoz Inc.

E-Law Admin/ Dezember 14, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

AmGen Inc. v. Sandoz Inc., 17-1277 Read AmGen Inc. v. Sandoz Inc., 17-1277 Returning once again after climbing and descending the appellate ladder several times, the court held that the defendant had not forfeited its preemption defense and that the Biologics Price Competition and Innovation Act preempts state law remedies for an applicant’s failure to comply with aspects of the

Weiterlesen

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty.

E-Law Admin/ Juni 19, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty., 16-466 Read Bristol-Myers Squibb Co. v. Superior Court of Cal., San Francisco Cty., 16-466 In a suit brought by plaintiffs, most of whom are not California residents, against Bristol-Myers Squibb Company (BMS) in California state court, alleging that the pharmaceutical company’s drug Plavix had damaged their health, the Supreme

Weiterlesen

Lawton v. Takeda Pharm. Co.

E-Law Admin/ November 22, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Lawton v. Takeda Pharm. Co., 16-1382 Read Lawton v. Takeda Pharm. Co., 16-1382 In a qui tam action under the False Claims Act (FCA), 31 U.S.C. section 3729 et seq., and the False Claims Acts of 28 different states and the District of Columbia, alleges that defendants conspired in a fraudulent marketing campaign that caused third-parties to submit false reimbursement

Weiterlesen

Hochendoner v. Genzyme Corp.

E-Law Admin/ Mai 23, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Hochendoner v. Genzyme Corp., 15-1446 Read Hochendoner v. Genzyme Corp., 15-1446 In consolidated actions arising out of the shortage of a medication that treats Fabry Disease, a rare genetic disorder that leaves afflicted persons unable to synthesize a key enzyme that helps the body break down fats, the District Court’s order of dismissal is affirmed for lack of Article III

Weiterlesen